← Leaderboards
Lin Xu
Ut Southwestern Medical Center
$424,763
Attributed
$849,526
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $437.4K · FY2021–24$500K$375K$250K$125K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$849,526 · 2
By mechanism
R21$849,526 · 2
Top collaborators
- Stephen X Skapek4 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Rene L Galindo$2,308,569
- Theodore Willis Laetsch$1,603,413
- Usman Hyder$268,563
- Michael Kyba$19,625,267
- Karla Gabriela Cano Hernandez$89,791
Others in their field
Other Emerging Leaders on “Malignant Childhood Neoplasm”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$99,102,100
- Leonard Freedman · Leidos Biomedical Research, Inc.$75,954,921
- Lynn Briscoe · Leidos Biomedical Research, Inc.$18,788,552
- Crystal Mackall · Children'S Hosp Of Philadelphia$16,938,059
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Elizabeth Fox · St. Jude Children'S Research Hospital$10,492,848
Research focus
Malignant Childhood NeoplasmMolecular BiologyGene ExpressionInnovationMalignant NeoplasmsMolecularComputational PipelinesGene DosageGenesHigh RiskDisorder RiskCell LineBiologicalCellsChildCommunitiesBiologyComputational AlgorithmGene Expression ProfilingClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsGenomicsBayesian MethodMutation
Grant awards (4)
Nominating vulnerabilities in fusion oncoprotein-driven rhabdomyosarcoma$182,090
R21 · FY2024 · CA
Nominating vulnerabilities in fusion oncoprotein-driven rhabdomyosarcoma$1
R21 · FY2024 · CA
Nominating vulnerabilities in fusion oncoprotein-driven rhabdomyosarcoma$230,010
R21 · FY2023 · CA
Identifying neuroblastoma drivers and bringing them to the clinic$437,425
R21 · FY2021 · CA